(Q43684650)

English

ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer

scientific article published on 11 November 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

immunohistochemistry

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

A Marije Hoogland

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Guido Jenster

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Wytske M van Weerden

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Jan Trapman

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Theo van der Kwast

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Monique J Roobol

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Fritz H Schröder

7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Mark F Wildhagen

8

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Geert Jlh van Leenders

9

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

publication date

11 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Modern Pathology

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

471-479

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

https://scigraph.springernature.com/pub.10.1038/modpathol.2011.176

0 references

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

ETS gene fusions in prostate cancer: from discovery to daily clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Role of the TMPRSS2-ERG gene fusion in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Antibody-based detection of ERG rearrangement-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Androgen receptor and prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands).

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Screening and prostate-cancer mortality in a randomized European study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naïve, node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

The discovery and application of gene fusions in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Diversity of TMPRSS2-ERG fusion transcripts in the human prostate

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

Response to ‘TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas’

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

21 January 2018

AR, the cell cycle, and prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.176

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/MODPATHOL.2011.176

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43684650&oldid=2102492313"